

Figure 17D shows complete amino acid sequences for human cardiac TnT (SEQ ID NO:14), rat cardiac TnT (SEQ ID NO:17), and rat fast skeletal TnT (SEQ ID NO:18), and the literature references therefor.

The foregoing sequences are also compiled and are available at the website (<http://genome.cs.unc.edu>).--

In Table 2, after "XXKKPE(P/A)KADDA" insert --(SEQ ID NO:1)--.

In Table 2, after "XPAPAAAPAAAP" insert --(SEQ ID NO:2)--.

In Table 2, after "XKVALGAXGGI" insert --(SEQ ID NO:3)--.

In Table 2, after "XXLKDITRRLKSI" insert --(SEQ ID NO:4)--.

In Table 2, after "XXKLVRPPVQ" insert --(SEQ ID NO:5)--.

In Table 2, after "XAHKSEIAHR" insert --(SEQ ID NO:6)--.

In Table 2, after "XPS(R/L)KFFVGGN" insert --(SEQ ID NO:7)--.

**REMARKS:**

A paper Sequence Listing and a computer readable form thereof, in accordance with 37 C.F.R. §§ 1.821 to 1.825, are being filed concurrently with applicants' Transmittal Letter dated June 23, 2000. In that Transmittal Letter, applicants request entry of the paper Sequence Listing after page 42 of the disclosure and prior to the claims. In the present Amendment and Response, applicants amend the disclosure to assign a SEQ ID NO to each amino acid sequence appearing in the disclosure and drawings. For the Examiner's convenience, Applicants enclose a copy of Table 2 upon which the SEQ ID NOs have been interlineated in red. It is submitted that no new matter has been entered. With the two submissions taken together, applicants are in full compliance with the requirements of 37 C.F.R. §§ 1.821 to 1.825.

Applicants submit that the application is now in condition for allowance, and early action in that regard is respectfully requested. If the Examiner would like to discuss the application or

this Amendment and Response, he is invited to telephone applicants' agents Carol Miernicki Steeg (Reg. No. 39,539) or Stephen Scribner (Reg. No. 44,452) at (613) 533-2342.

Applicants believe that this Amendment and Response is being timely filed by the deadline of June 24, 2000. However, should an extension of time be required, Applicants request that this Amendment and Response be considered as a Petition for an extension of time of one month under 37 C.F.R. § 1.136(a).

Any fees that may be due in respect of the above Amendment and Response, or any fee for an extension of time that may be required under 37 C.F.R. § 1.17(a)(1), should be charged to Deposit Account No. 17-0110.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Carol Miernicki Steeg".

Carol Miernicki Steeg  
Registration No. 39,539

PARTEQ Innovations  
Queen's University  
Kingston, Ontario  
K7L 3N6  
(613) 533-2342

Table 2: Identification of proteins affected by ischemia and ischemia/reperfusion by amino acid sequencing

Amino Acid Sequence	Protein	Residue Number	First Identified Amino Acid (pmole)	Tissue Sampled
XXKKPE(P/A)KADDA (SEQ ID NO: 1)	myosin light chain1	1-12	2.6	global ischemia myofibrils & 60I/45RP tissue
XPAPAAAPAAAP (SEQ ID NO: 2)	myosin light chain1	20-31	6.0	global ischemia myofibrils
XKVALGAXGGI (SEQ ID NO: 3)	malate dehydrogenase	1-11	3.2	60I/45 RP tissue
XXLKDITRLKSI (SEQ ID NO: 4)	ATP g synthase chain	1-13	4.5	60I/45RP tissue
XXKLVRPPVQ (SEQ ID NO: 5)	ATP synthase oligomycin conferring protein	1-10	2.3	60I/45RP tissue
XAHKSEIAHR (SEQ ID NO: 6)	serum albumin	1-10	12.4	60I/45RP effluent
XPS(R/L)KFFVGGN (SEQ ID NO: 7)	triose phosphate isomerase	1-11	9.9	60I/45RP effluent